

Table S1 Clinical benefit according to metastatic site at baseline. Data were reported as median and 95% confidence intervals.

Cohort A			Cohort B		
	OS	PFS		OS	PFS
Liver (n=26)	20.6 months (9.9-NE)	8.9 (6.6-12.5)	Liver (n=46)	6.8 (5.6-8.2)	5.7 (4.2-6.6)
Brain (n=14)	NE (8.2-NE)	12.5 (6.6-NE)	Brain (n=37)	8.3 (6.6-11.7)	6.9 (5.2-9.4)
Skin (n=16)	NE	NE	Skin (n=16)	10.3 (5.7-14.0)	7.0 (4.0-9.9)

Table 2S Second-line treatment

	Cohort A (n=46)	Cohort B (n=32)
Pembrolizumab	9	5
Nivolumab	19	23
Ipilimumab	1	2
Encorafenib	2	1
Binimetinib	2	1
Not specified	13	0